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Medications to relieve pain and inflammation are among the 
most commonly used drugs in our society today. The traditional 
non-selective non-steroidal anti-inflammatory drugs (NSAIDs) 
and the selective cyclooxygenase-2 (COX-2) inhibitors are ef-
fective anti-inflammatory and analgesic agents used in a wide 
range of acute and chronic medical conditions. The gastrointes-
tinal adverse effects are well recognised. There is now strong 
evidence to suggest that both the traditional NSAIDs (exclud-
ing aspirin) and the COX-2 inhibitors are associated with an 
increased risk of thrombotic events (including myocardial 
infarction (MI) and stroke) and excess mortality both in patients 
with and without pre-existing cardiovascular disease. 
Although their benefits in terms of symptomatic relief when 
used appropriately are unquestioned, there is concern that the 
NSAIDs and COX-2 inhibitors  are prescribed or recommended 
by doctors and pharmacists (many of these drugs are available 
without prescription) for trivial or inappropriate indications 
without due consideration regarding their potential adverse 
effects. The traditional NSAIDs, freely available in public sector 
facilities, are often requested by patients and perceived by 
doctors as a ‘cheap’ and convenient way to keep patients happy 
and terminate a consultation. Some practitioners seem unaware 
of the magnitude of the problem or of the number needed to 
treat to cause harm. Many patients receive these drugs before 
other pharmacological or non-pharmacological treatments 
have been attempted. This has led to over-prescribing of 
these agents, particularly in an elderly population, in whom 
associated cardiovascular disease is the leading cause of death. 
We aim to highlight the importance of these cardiovascular 
effects, and will summarise the clinical data on cardiovascular 
events, provide an overview of the basic science underlying 
the cardiovascular side-effects, and provide suggestions for 
prescribing COX-2 inhibitors and NSAIDs in patients with or at 
risk of developing vascular disease. 
Background 
The traditional non-selective NSAIDs (naproxen, ibuprofen, 
diclofenac), which inhibit both forms of the COX isoenzyme 
(COX-1 and COX-2), are associated with significant gastrointes-
tinal side-effects. As these side-effects were believed to be medi-
ated primarily by COX-1 inhibition, newer selective NSAIDs or 
COX-2 inhibitors (rofecoxib, celecoxib, parecoxib, valdecoxib) 
were developed from the late 1990s to primarily inhibit the 
COX-2 isoenzyme. Subsequent studies reporting a lower inci-
dence of gastrointestinal side-effects with COX-2 inhibitors, and 
heavy promotion, with direct-to-consumer advertising, led to 
an explosion in the use of the COX-2 inhibitors worldwide. 
The first sign that COX-2 inhibitors might increase 
cardiovascular risk was from the VIGOR (Vioxx Gastrointestinal 
Outcomes Research) trial.1 This randomised controlled trial 
reported a 50% reduction in serious gastrointestinal side-
effects, but a 5-fold increase in thromboembolic cardiovascular 
events (primarily acute MI) in patients taking rofecoxib 
50 mg daily compared with naproxen 1 000 mg daily at 9 
months. Having naproxen as a comparator complicated the 
interpretation, which led to the false notion that naproxen 
was cardioprotective. The increase in cardiovascular risk with 
rofecoxib was later confirmed by the APPROVe (Adenomatous 
Polyp Prevention on Vioxx) trial, which showed a 2-fold 
increase in cardiovascular events with 25 mg/d of rofecoxib 
compared with placebo in patients with a prior adenomatous 
polyp.2 
These data led to the withdrawal of rofecoxib from the world 
market in September 2004. Subsequently, the APC (Adenoma 
Prevention with Celecoxib) trial, which compared celecoxib 
with placebo, reported a 3-fold increase in cardiovascular risk 
in patients taking celecoxib 400 mg twice daily.3 Another meta-
analysis of two trials in high-risk patients taking valdecoxib 
who had recently undergone coronary artery bypass surgery, 
showed a significant 3-fold increase in cardiovascular events.4 
This led to the withdrawal of valdecoxib in April 2005. 
With two COX-2 inhibitors withdrawn from the world 
market, attention then turned to the cardiovascular safety of 
the traditional non-selective NSAIDs with conflicting studies 
implicating higher doses of ibuprofen and diclofenac with 
increased cardiovascular events. 
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Against this backdrop in February 2005, the US Food 
and Drug Administration requires that all COX-2 inhibitors 
and non-selective NSAIDs carry a warning highlighting 
the potential for increased risk of cardiovascular events.5 
Similarly, the Medicines Control Council of South Africa 
has required labelling of all COX-2 inhibitors, but has made 
no recommendation about the cardiovascular safety of the 
traditional NSAIDs.6 
Data on risk of cardiovascular events 
Drawing conclusions from the numerous data on the COX-
2 inhibitors and NSAIDs is not straightforward, as most of 
the data were obtained from post-hoc and non-prespecified 
analyses of randomised trials with many trials lacking a 
placebo arm. Although the current data have their limitations, it 
is possible to draw a number of conclusions. 
In patients with and without cardiovascular disease, there 
is good evidence to suggest that the COX-2 inhibitors are 
associated with an increased incidence of cardiovascular events. 
There is growing evidence to suggest that these adverse effects 
appear to be a ‘class effect’ of the COX-2 inhibitors with a 
dose-dependent increase in risk. There are numerous studies 
that indicate different degrees of risk associated with different 
COX-2 inhibitors, but to date there have been no head-to-head 
comparisons of the various COX-2 inhibitors.7 Cardiovascular 
risk seems to increase from the start of therapy and continues 
throughout the duration of treatment.8 
A recently published meta-analysis of 121 randomised trials 
that assessed the effects of COX-2 inhibitors compared with 
placebo on the risk of cardiovascular events, reported a 42% 
relative increase in the incidence of serious vascular events 
(mainly myocardial infarction) – incidence 1.2%/year taking 
COX-2 inhibitors v. 0.9%/year taking placebo. No significant 
difference was observed between the COX-2 inhibitors studied 
(rofecoxib, celecoxib). In absolute terms, 3 extra people will 
have a vascular event per 1 000 per year.9 
A recently published systematic review of 23 observational 
studies found similar results.10 Rofecoxib was associated with 
a 35% relative increase in cardiovascular events compared to 
placebo with a 2-fold increase in risk with doses in excess of 
25 mg/day. The risk was shown to increase early in therapy, 
probably with the first dose.8 The data on celecoxib have been 
inconsistent. A meta-analysis and a case-control study suggest 
that celecoxib is associated with increased cardiovascular 
events at a dose > 400 mg/day.3,11,12 Another meta-analysis 
failed to demonstrate an increase in cardiovascular risk in 
patients with predominantly rheumatological disorders and 
Alzheimer's disease. However, many of these studies were not 
originally designed to assess cardiovascular risk and many 
were of short duration.13 
Larger trials are needed to accurately determine the 
magnitude of risk of the individual COX-2 inhibitors at varying 
doses. The PRECISION (Prospective Randomized Evaluation 
of Celecoxib Integrated Safety v. Ibuprofen or Naproxen) trial 
is planned to investigate the relative safety of these drugs in 
21 000 patients.14 
Studies of the traditional, non-selective NSAIDs have 
been more difficult to interpret. As NSAIDs were originally 
developed for the relief of pain, long-term placebo-controlled 
trials evaluating cardiovascular events have not been 
conducted. Nevertheless, conflicting available data suggest that 
the cardiovascular risks may be significant but lower than with 
the COX-2 inhibitors. 
A meta-analysis of 91 trials that compared a COX-2 inhibitor 
to a non-selective NSAID in patients without cardiovascular 
disease, demonstrated a similar incidence of serious vascular 
events in patients taking high-dose (ibuprofen 800 mg 3 times 
a day, diclofenac 75 mg 2 times a day) non-selective NSAIDs 
(1.0%/year v. 0.9%/year). This meta-analysis was unable to 
conclude whether lower doses of NSAIDs would have the same 
effect.9 
In a systematic review, diclofenac and indomethacin carried 
the highest risk, with a 40% relative increase in cardiovascular 
events, but dose-effects could not be assessed.10 Although 
there is agreement between randomised and non-randomised 
studies that naproxen appears to be neutral for MI risk, 
investigators recently halted the ADAPT (Alzheimer’s Disease 
Prevention Trial) because of an excess of cardiovascular events 
in participants randomised to naproxen.9,15 
Another meta-analysis of 13 randomised trials in patients 
with joint disease and Alzheimer’s disease showed a non-
significant trend towards increased cardiovascular risk in 
Alzheimer’s disease trials, but not in trials of joint disease.16 
The most convincing evidence that cardiovascular risk is 
dose-dependent comes from an analysis of the Nurses’ Health 
study that suggests that frequent use (> 22 days/month or > 
or = 15 tablets per week) of non-selective NSAIDs (73% used 
ibuprofen, 14% used naproxen) in healthy women without 
cardiovascular disease resulted in a 44 - 86% relative increase 
in cardiovascular events compared with non-users.17 This 
effect of NSAIDs did not differ according to the presence or 
absence of chronic conditions. This study also demonstrated 
that paracetamol led to a 35% relative increase in cardiovascular 
events in patients consuming paracetamol tablets > 22 days per 
month. 
While all the above data concern patients without known 
cardiovascular disease, the limited data in patients with 
established cardiovascular disease are of particular concern. A 
large Danish registry of 58 432 post-MI patients demonstrated 
that both COX-2 inhibitors (rofecoxib, celecoxib) and non-
selective NSAIDs (ibuprofen, diclofenac) were associated with a 
2 - 3-fold increase in mortality and a trend for an increased risk 
of rehospitalisation for MI.18 These adverse effects were dose-
related and most patients were receiving treatment for a short 
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time (1 month on average). In absolute numbers, 14 patients 
treated with a celecoxib, 24 patients treated with diclofenac, 
and 45 patients treated with ibuprofen for 1 year will result in 
1 additional death. These data confirm that these drugs should 
be used with particular caution in high-risk patients and should 
preferably be avoided unless absolutely essential. 
Mechanism of adverse cardiovascular 
effects 
The reported adverse effects are biologically plausible given 
our understanding of the role of COX inhibition in vascular 
pathophysiology. Within the vascular lumen, COX-1 and 
COX-2 play an important role in the interaction between 
platelets and endothelial cells and in thrombogenesis. 
Activated platelets produce COX-1-dependent thromboxane 
A2, which acts as a platelet agonist and vasoconstrictor 
(prothrombotic). Endothelial and smooth-muscle cells produce 
COX-2-dependent prostacyclin, especially after cell damage.  
Prostacyclin has  vasodilatory effects and is a platelet antagonist 
(inhibits thrombogenesis). COX-2 inhibitors suppress 
endothelial production of prostacyclin, leaving prothrombotic 
platelet thromboxane A2 mediated by COX-1 relatively 
unopposed. With loss of the antiplatelet and vasodilatory 
effects of prostacyclin, a relative excess of thromboxane A2 
would favour vasoconstriction, platelet aggregation and 
thrombosis. In addition, the COX-2 inhibitors can cause 
sodium retention, a reduction in glomerular filtration rate and 
exacerbation of hypertension, which may promote an increased 
risk of cardiovascular events. 
Cell damage, atherosclerotic plaques, and laminar shear 
forces selectively upregulate the expression of COX-2 by 
endothelial cells to maintain homeostasis. COX inhibition by 
any NSAID or COX-2 inhibitor can be expected to upset the 
thrombotic equilibrium, increasing the risk of cardiovascular 
events.19 
How do we explain the variable side-effects between 
the NSAIDs and COX-2 inhibitors of different drugs of the 
same class? Not all NSAIDs and COX-2 inhibitors are the 
same. Owing to important structural, pharmacodynamic 
and pharmacokinetic differences, the different traditional 
NSAIDs have variable COX-1 and COX-2 inhibiting properties. 
Increasing degrees of COX-2 selectivity are associated with 
augmented cardiovascular risk.  The NSAIDs, in increasing 
order of COX-2 selectivity, are naproxen, ibuprofen and 
diclofenac.  Similarly, different COX-2 inhibitors have varying 
effects of COX-2 inhibition. The COX-2 inhibitors, with 
increasing order of COX-2 selectivity, are celecoxib, rofecoxib 
and etoricoxib.20  The above properties may partly explain 
the different gradients of risk associated with different COX-2 
inhibitors and NSAIDs. 
How do we explain the dose-dependent increase in risk? 
NSAIDs display temporary and reversible binding to COX and 
therefore, in theory, will lead to greater inhibition at higher 
doses. Conversely, the COX-2 inhibitors display irreversible 
covalent binding to COX, which may partly explain the greater 
inhibition of COX-2 during intermittent use and at lower doses. 
Recommendations for use 
COX-2 inhibitors are contraindicated in patients with ischaemic 
heart disease (including postoperative coronary artery bypass 
graft patients) or stroke, and these patients should be switched 
to alternative treatments if possible. NSAIDs are not without 
risk and should be used with caution, especially in patients 
with ischaemic heart disease or at high risk thereof because of 
hypertension, diabetes, smoking or hypercholesterolaemia. 
Since NSAIDs and COX-2 inhibitors are mostly used for 
symptom relief, rather than disease modification, these drugs 
should be prescribed only when non-pharmacological and 
other lower-risk pharmacological drugs (aspirin, paracetamol, 
narcotic analgesics) have failed. A NSAID with a low COX-2 
selectivity should be the preferred choice (see above).  Health 
care providers should assess the patient’s individualised risk/
benefit ratio before prescribing a NSAID or COX-2 inhibitor, 
and prescribe the lowest dose of these drugs for the shortest 
possible time necessary to control symptoms. 
Patients should be periodically monitored for adverse side-
effects and the ongoing need for NSAID or COX-2 inhibitor use. 
Reflex repeat prescriptions should be avoided. Taking low-dose 
aspirin with a NSAID or COX-2 inhibitor has not been studied 
sufficiently adequately to make a firm recommendation, but it 
is clear that this combination will increase gastrointestinal risk. 
Most importantly, perhaps we all need to scrupulously re-
examine our prescribing habits. The NSAIDs and paracetamol 
are among those agents labelled as ‘troos medisyne’. These cheap, 
supposedly harmless medications are added onto the script at 
the patient’s request along with the laxative, nocturnal sedative 
or skin cream. The recent revelation of the magnitude of 
potential harm associated with NSAIDs and paracetamol after 
several decades of prescribing them to patients with vascular 
disease, often for tenuous indications, is sobering. 
Conclusion 
Significant increases in risk of cardiovascular events in NSAID 
users have been found in clinical trials, especially in patients 
taking COX-2 inhibitors. Although two COX-2 inhibitors have 
been taken off the market, other COX-2 inhibitors and NSAIDs 
are still readily available to doctors and patients. COX-2 inhibi-
tion by COX-2 inhibitors and NSAIDs results in a disturbance 
in the equilibrium of COX-1 and COX-2, which predisposes to a 
prothrombotic state and increased cardiovascular events. When 
prescribing NSAIDs and COX-2 inhibitors, doctors should care-
fully weigh the benefits of treatment against potential gastroin-
testinal and cardiovascular harm. Patients with established car-
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diovascular disease or at risk for cardiovascular events should 
not be treated with COX-2 inhibitors and NSAIDs unless it is 
absolutely essential and all other treatment options have been 
explored. The number of patients one needs to treat with these 
agents before causing harm is alarmingly small, and perhaps 
the packaging of the traditional NSAIDs, like the COX-2 inhibi-
tors, should carry a health warning! 
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